Annis Gardner Whiting Capital Advisors’s GSK GSK Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,540	Closed	-$140K	–	708
2026 Q1	$140K	Sell	2,540 -1,004	-28%	-$54.4K	0.02%	375
2025 Q4	$174K	Buy	3,544 +2,184	+161%	+$102K	0.03%	308
2025 Q3	$58.7K	Sell	1,360 -764	-36%	-$29.8K	0.01%	473
2025 Q2	$81.6K	Buy	2,124 +680	+47%	+$26K	0.03%	333
2025 Q1	$56K	Hold	1,444	–	–	0.02%	342
2024 Q4	$48.9K	Hold	1,444	–	–	0.01%	347
2024 Q3	$59.1K	Buy	1,444 +1,360	+1,619%	+$55.6K	0.02%	347
2024 Q2	$3.27K	Sell	84 -287	-77%	-$12.1K	﹤0.01%	817
2024 Q1	$15.9K	Buy	+371	New	+$15.3K	0.01%	601

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's GSK Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of GSK (GSK) in Q2 2026, closing a stake of 2,540 shares — an estimated $140K sold.

Annis Gardner Whiting Capital Advisors first reported a position in GSK in Q1 2024 and held it in 9 quarters. The position peaked at $174K in Q4 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Annis Gardner Whiting Capital Advisors reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Annis Gardner Whiting Capital Advisors sold 2,540 GSK shares in Q2 2026, an estimated $140K.
Annis Gardner Whiting Capital Advisors first reported a position in GSK in Q1 2024 and held it in 9 quarters.
Annis Gardner Whiting Capital Advisors's GSK position peaked at $174K in Q4 2025.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.